AndhraNews.net
Home » Business News » 2013 » October » October 17, 2013

ACTIVAERO FURTHER STRENGTHENS CYSTIC FIBROSIS COMPETENCE THROUGH NEW RESEARCH COLLABORATION WITH STANFORD UNIVERSITY


October 17, 2013 - London

Activaero GmbH /ACTIVAERO FURTHER STRENGTHENS CYSTIC FIBROSIS COMPETENCE THROUGH NEW RESEARCH COLLABORATION WITH STANFORD UNIVERSITY . Ad hoc announcement according to § 15 WpHG. Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Gemuenden/Wohra, Germany, October 17, 2013 - Activaero GmbH, the therapeutic area specialist for respiratory diseases focusing on novel, pharmacoeconomically meaningful treatment solutions for severe lung diseases, today announced that it has entered into a research collaboration with Stanford University, one of the world's leading institutions for research and education. The parties are going to jointly evaluate the potential of Activaero's flow and volume regulated FAVORITE inhalation approach in the treatment of Cystic Fibrosis patients with hypertonic saline compared to treatment with standard nebulizers.

The proof-of-concept study will specifically assess for changes in small airway pulmonary function parameters after a therapy session of 7% hypertonic saline delivered by a standard Pari-LC Jet nebulizer and FAVORITE inhalation as well as differences in sputum production with each inhalational device. In addition, differences in the tolerability of 7% hypertonic saline delivered with each inhalational device will be monitored.

FAVORITE inhalation allows for optimum drug distribution across the entire lung importantly including the small airways. This most distal region of the lung is typically not accessible with standard nebulizer systems due to the obstructions caused by scarred tissue and mucus in the lungs of Cystic Fibrosis patients.

"Besides our internal research focus on severe asthma, Activaero has always been fully dedicated to improving the quality of life of patients suffering from Cystic Fibrosis with its inhalation approach. As there are a variety of therapeutic approaches to manage the symptoms and consequences of the disease, we are investigating a whole portfolio of solutions together with high caliber partners such as Stanford University", commented Gerhard Scheuch, Founder and Chief Executive Officer of Activaero GmbH. "Currently, hypertonic saline treatments are performed with conventional nebulizers delivering only a small fraction of the solution to the small airways. A higher dose in the periphery of the lungs may help improving lung function and sputum production."


About Cystic Fibrosis

Cystic Fibrosis (CF), also known as mucoviscidosis, is one of the most common genetic disorders amongst Caucasians. The disease is inherited recessively with an improved but still rather low life expectancy with a median age of currently 33.4 years according to the World Health Organization. CF leads to chronic inflammations of the respiratory tract and also affects other organs, such as the digestive tract, liver, sweat glands and reproductive organs. Symptoms include heavily salty-tasting sweat, coughing similar to whooping cough, severe bronchitis and pneumonia, an increased production of tough and viscous mucus that leads to frequent bacterial infections as well as disturbed digestions and male sterility. Most patients die from cardiorespiratory complications caused by those symptoms.

About FAVORITE

FAVORITE is Activaero's proprietary, clinically and commercially proven inhalation approach to effectively treat severe respiratory and pulmonary diseases. FAVORITE actively regulates inspiration flow and inhalation volume. By guiding, controlling and supporting the patient's breathing, optimal inhalation patterns are created. Using FAVORITE, inhaled drugs can be selectively targeted to pre-defined lung regions hence unlocking completely new opportunities for novel aerosol therapies.

About Activaero

Activaero is a therapeutic area specialist developing new, pharmacoeconomically meaningful treatment solutions for patients suffering from severe respiratory diseases, including asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis (CF), Idiopathic Pulmonary Fibrosis (IPF) and Pulmonary Hypertension. Activaero was founded in 1998 in Germany and is a privately held company with offices in Germany near Frankfurt and Munich as well as in Dublin, Ohio (USA).

www.activaero.de


About Stanford University

Stanford University is one of the world's leading research universities. Stanford is known for its entrepreneurial character, drawn from the legacy of its founders, Jane and Leland Stanford, and its relationship to Silicon Valley. Research and teaching stresses interdisciplinary approaches to problem solving. Areas of excellence range from the humanities to social sciences to engineering and the sciences. Stanford is located in California's Bay Area, one of the most intellectually dynamic and culturally diverse areas of the nation.

www.stanford.edu


Contact us:

Activaero GmbH Media Contact
Christian Pangratz Anne Hennecke
Chief Business Officer MC Services AG
t: +49-89-897969-65 t: +49-89-210228-18
e: christian.pangratz@activaero.de e: anne.hennecke@mc-services.eu
www.activaero.de
Press release (PDF)



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Activaero GmbH via Thomson Reuters ONE

HUG#1736249

GlobeNewswire

Comment on this story

Share